Anavex Life Sciences Corp (AVXL)

[rocalinda]

I don't recall receiving the proxy for annual meeting this early. Dr. M most be anxious to share. Expect very very good news:

ANAVEX LIFE SCIENCES CORP.
51 W 52nd Street, 7th Floor, New York, NY 10019

Dear Stockholder:

You are invited to attend the 2020 Annual Meeting of Stockholders of Anavex Life Sciences Corp. which will be held on Tuesday, April 7, 2020, 10:00 a.m., local time, at the offices of K&L Gates LLP, 599 Lexington Avenue, New York, NY 10022.

Details regarding the meeting and the business to be conducted are described in the accompanying proxy statement. The proxy statement contains information on matters to be voted upon at the 2020 Annual Meeting of Stockholders or any adjournments of that meeting. In addition to considering the matters described in the proxy statement, we will report on matters of interest to our stockholders.

Whether or not you plan to attend the meeting, we encourage you to vote as soon as possible to ensure that your shares are represented at the meeting. The proxy statement explains more about proxy voting, so please read it carefully. Please complete, date, sign and return the accompanying proxy in the enclosed envelope to ensure the presence of a quorum at the meeting. Even if you have voted by proxy, and you attend the meeting, you may, if you prefer, revoke your proxy and vote your shares in person. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you will not be permitted to vote in person at the meeting unless you first obtain a legal proxy issued in your name from the record holder.

The proxy statement is dated February 20, 2020 and is expected to be first mailed to stockholders of Anavex Life Sciences Corp. on or about February 26, 2020. The Proxy Statement and 2019 Annual Report are available at http://www.viewproxy.com/Anavex/2020.

We look forward to your continued support.

Sincerely,

/s/ Christopher Missling, PhD.

Christopher Missling, PhD.
Chief Executive Officer and

Chairman of the Board of Directors